Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Dregalla Patent Holdco LLC focuses on the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. This indicates an active period of negotiation with the patent office regarding biological or pharmaceutical innovations. The volume of pending actions suggests a portfolio with multiple active threads in the examination process.
The data shows that prosecution is handled by 1 distinct examiner and 1 distinct art unit. This is a high degree of concentration for a portfolio with multiple pending matters, as it places the entirety of the current workload under a single individual's review. For the practitioner, this means that the examiner's interpretation of the prior art will have a significant impact on multiple applications.
BARRON, SEAN C is the busiest examiner for this company, with 2 busiest examiner pending office actions. Since this examiner is responsible for the 2 busiest examiner pending office actions currently identified, the company's success in the Biotechnology & Pharmaceuticals area is heavily tied to this single relationship. Practitioners should prioritize a consistent dialogue with this examiner to efficiently move the pending matters toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 2 | 52.7% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16794051 | Acellular Regenerative Products and Preservation Media | BARRON, SEAN C | — |
| 14945128 | Acellular Regenerative Products and Methods of Their Manufacture | BARRON, SEAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16794051 | Acellular Regenerative Products and Preservation Media | BARRON, SEAN C | — |
| 14945128 | Acellular Regenerative Products and Methods of Their Manufacture | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16794051 | Acellular Regenerative Products and Preservation Media | BARRON, SEAN C | 1653 | §101§103§112DP | Non-Final OA | — | Pending | Feb 18, 2020 |
| 14945128 | Acellular Regenerative Products and Methods of Their Manufacture | BARRON, SEAN C | 1653 | §101§103§112DP | Non-Final OA | — | Pending | Nov 18, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDregalla Patent Holdco LLC has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean C Barron has the most, with 2 of Dregalla Patent Holdco LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
